References
1. Coronavirus disease (COVID-19) Situation Report– 106.
https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200505covid-19-sitrep-106.pdf?sfvrsn=47090f63_2.
Accessed 14th May 2020
2. DerSimonian R, Laird N. Meta-analysis in clinical trials.Control Clin Trials. 1986;7(3):177-188.
3. Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard
deviation from the sample size, median, range and/or interquartile
range. BMC Med Res Methodol. 2014;14:135.
4. Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane
Collaboration’s tool for assessing risk of bias in randomised trials.BMJ. 2011;343:d5928.
5. Bessiere F, Roccia H, Deliniere A, et al. Assessment of QT Intervals
in a Case Series of Patients With Coronavirus Disease 2019 (COVID-19)
Infection Treated With Hydroxychloroquine Alone or in Combination With
Azithromycin in an Intensive Care Unit.JAMA Cardiol 2020 [E-pub
ahead of print] https://dx.doi.org/10.1001/ jamacardio.2020.1787.
6. Mercuro NJ, Yen CF, Shim DJ, et al. Risk of QT Interval Prolongation
Associated With Use of Hydroxychloroquine With or Without Concomitant
Azithromycin Among Hospitalized Patients Testing Positive for
Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020 [E-pub
ahead of print], https://dx.doi.org/10.1001/jamacardio.2020.1834.
7. Saleh M, Gabriels J, Chang D, et al. The Effect of Chloroquine,
Hydroxychloroquine and Azithromycin on the Corrected QT Interval in
Patients with SARS-CoV-2 Infection. Circ Arrhythm Electrophysiol.2020. [E-pub ahead of print], https://dx.doi.org/10.1161/
CIRCEP.120.008662.
8. Chang D, Saleh M, Gabriels J, et al. Inpatient Use of Ambulatory
Telemetry Monitors for COVID-19 Patients Treated with Hydroxychloroquine
and/or Azithromycin. J Am Coll Cardiol. 2020 . [E-pub ahead of
print], https://dx.doi.org/10.1016/j.jacc.2020.04.032.